Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NNVCBullishCorporate Developmentsnews

High materiality8/10

NanoViricides Advances NV-387 MPox Phase II with Ebola Contingency and ODD Upside

Jun 22, 2026, 9:34 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive near-term catalysts (Phase II start, potential ODD benefits, SNS opportunities) could improve NNVC sentiment, though execution risk remains and regulatory milestones are uncertain.

AI summary

What happened, with direct paths to the underlying reporting

NanoViricides reports NV-387 Oral Gummies shipped for a Phase II MPox trial in the DRC, with enrollment to start after staff training in a few weeks. Site preparations continue in India/DRC while delays from site changes and travel restrictions amid a PHEIC persist. If Phase II reads favorably and ODD is granted, NV-387 could become a pivotal pandemic-response asset with potential SNS-related opportunities.

NV-387 Oral Gummies shipped for Phase II MPox trial in DRC. Enrollment to begin after staff training.
CRO prep in India and DRC; enrollment after training in weeks.
Phase II delayed by site change and travel restrictions amid PHEIC.
ODD designation pursued; potential tens of millions in value.
MPox Clade I rising in the US; vaccines waning.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.